Epidemiology of pancreatic cancer in Ukraine and Zaporizhzhia region
DOI:
https://doi.org/10.14739/2409-2932.2024.2.299555Keywords:
pancreatic neoplasms, epidemiology, morbidity, mortalityAbstract
The aim of the work is to analyze the incidence and mortality of pancreatic cancer (PC) in Ukraine and the Zaporizhzhia region to highlight and compare the organization of oncological care, the benefits of prevention, and early diagnosis of this disease.
Materials and methods. The analysis of the data of the National Cancer Registry of Ukraine for 2014–2022 was carried out. The information used in the research was reviewed and approved by the Commission on Bioethics of Zaporizhzhia State Medical and Pharmaceutical University, an extract from protocol No. 10 dated 12/21/2023. The data analysis was carried out using Microsoft Excel spreadsheets and the applied statistical program Statistica® for Windows 13.0 (StatSoft Inc., USA, license No. JPZ804I382130ARCN10-J).
Results. According to GLOBOCAN data (2022), RP ranks 14th in the world and 12th in Ukraine in morbidity and is one of the leading causes of mortality. Every year there is an increase in cases of this pathology. Morbidity and mortality rates are significantly higher in countries with a high level of development, while the survival rate does not reveal such a dependence. Mortality from PC in Ukraine is 76.9–82.3 %, in the Zaporizhzhia region 86.2–99.5 % with positive dynamics. Detection of early stages of PC in Ukraine and the Zaporizhzhia region is at the level of 26.0–36.4 %, 30.7–43.6 %, respectively, diagnosis of advanced stages is at the level of 43.8–56.3 % across Ukraine, in the Zaporizhzhia region – 58.6–63.2 %. In Ukraine, 25.3–31.9 % of primary patients are covered by special treatment, the regional indicator is 17.9–26.6 % with positive dynamics. The effectiveness of primary prevention of PC in Ukraine reaches 3.3 %, the regional indicator does not exceed 3.0 %.
Conclusions. Improvement of preventive measures, selection of groups at risk of development of PC, modification of lifestyle are factors for improvement of prognosis and survival of patients with PC.
References
Bray F, Colombet M, Mery L, Piñeros M, Znaor A, Zanetti R, Ferlay J, editors. Cancer incidence in five continents Volume XI. Lyon: International Agency For Research On Cancer ; Geneva; 2021. https://publications.iarc.fr/597
Yabroff KR, Wu XC, Negoita S, Stevens J, Coyle L, Zhao J, et al. Association of the COVID-19 Pandemic With Patterns of Statewide Cancer Services. J Natl Cancer Inst. 2022;114(6):907-909. doi: https://doi.org/10.1093/jnci/djab122
Global burden of gastrointestinal cancers [Internet]. Iarc.fr. 2022. Available from: https://gco.iarc.fr/stories/gastro-intestinal/en
Gaidhani RH, Balasubramaniam G. An epidemiological review of pancreatic cancer with special reference to India. Indian J Med Sci. 2021;73(1):99-109. doi: https://doi.org/10.25259/IJMS_92_2020
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33. doi: https://doi.org/10.3322/caac.21708
Cancer (IARC) TIA for R on. Global Cancer Observatory [Internet]. gco.iarc.fr. 2022. Available from: https://gco.iarc.fr/en
Corredor C, Piñeros M, Wiesner C, de Vries E. Using administrative registries as a source for population-based cancer incidence and mortality. BMC Cancer. 2024;24(1):232. doi: https://doi.org/10.1186/s12885-023-11754-w
Wang S, Zheng R, Li J, Zeng H, Li L, Chen R, et al. Global, regional, and national lifetime risks of developing and dying from gastrointestinal cancers in 185 countries: a population-based systematic analysis of GLOBOCAN. Lancet Gastroenterol Hepatol. 2024;9(3):229-37. doi: https://doi.org/10.1016/S2468-1253(23)00366-7
Yuan S, Chen J, Ruan X, Sun Y, Zhang K, Wang X, et al. Smoking, alcohol consumption, and 24 gastrointestinal diseases: Mendelian randomization analysis. Elife. 2023;12:e84051. doi: https://doi.org/10.7554/eLife.84051
Surveillance, Epidemiology, and End Results Program (SEER). SEER*Stat Databases: SEER November 2020 Submission. Bethesda (MD): Surveillance Research Program, National Cancer Institute; 2020 [cited 2024 Apr 14]. Available from: https://seer.cancer.gov/data-software/documentation/seerstat/nov2020/
Surveillance, Epidemiology, and End Results Program (SEER). SEER*Explorer: An interactive website for SEER cancer statistics. Bethesda (MD): Surveillance Research Program, National Cancer Institute; 2021 Sep 27 [cited 2024 Apr 14]. Available from: https://seer.cancer.gov/explorer/
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
